A revolutionary leukaemia drug has given hope to patients as it kills nearly 90 per cent of their cancer in the first dose.
Gazyva, which so powerful it can send patients into shock, comes with a whopping 42,000 dollar bill, News.com.au reported.
Though the drug has been approved for use in Australia but not yet subsidised by the Pharmaceutical Benefits Scheme and has some serious side effects including increased risk of infections, including lower white blood cell counts and reduce the ability of the blood to clot, fever, cough, and muscle and joint pain.
A study published in the New England Journal of Medicine earlier this year showed Gazyva delayed the progression of the cancer in patients using the drug in combination with an older chemotherapy by 26.7 months, 15 months longer than progression free survival in patients using standard treatment.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app